Cargando…

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

Detalles Bibliográficos
Autores principales:	Cordoba, R., Falchi, L., Phillips, T., de Vos, S., Nijland, M., Offner, F., Bykhovski, I., Wu, J., Wang, L., Rana, A., Abrisqueta, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430754/ http://dx.doi.org/10.1097/01.HS9.0000847724.59361.c7

Ejemplares similares

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
por: Belada, D., et al.
Publicado: (2022)

P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
por: Roost Clausen, Michael, et al.
Publicado: (2023)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Wahlin, B. E., et al.
Publicado: (2022)

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
por: Clausen, M. R., et al.
Publicado: (2022)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023)

COLLABORATION AGREEMENT No. K 1215
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2005)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
por: Jurczak, Wojciech, et al.
Publicado: (2023)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

1215. The Impact of MRSA Nasal PCR on Antibiotic De-escalation
por: Silverman, Adam, et al.
Publicado: (2023)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023)

P1215: CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF T FOLLICULAR HELPER SUBSETS IN FOLLICULAR LYMPHOMA
por: Yang, Zhi-Zhang, et al.
Publicado: (2023)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
por: Kersten, Marie José, et al.
Publicado: (2022)

PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
por: Sehn, L. H., et al.
Publicado: (2022)

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison
por: Cordoba, Raul, et al.
Publicado: (2022)

1215. Geographic Distribution of Staphylococcus aureus With Reduced Sensitivity and Resistance to Vancomycin in the Dominican Republic
por: Mena Lora, Alfredo J, et al.
Publicado: (2018)

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
por: Li, Tommy, et al.
Publicado: (2022)

P902: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY
por: Fazio, F., et al.
Publicado: (2022)

1215. A Mixed Methods Study on Severe Bacterial Infections in People Who Inject Drugs
por: Hrycko, Alexander, et al.
Publicado: (2021)

Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
por: Li, Jianglei, et al.
Publicado: (2022)

Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
por: Castagna, Luca, et al.
Publicado: (2015)

Successful Outcome of Autologous Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors
por: Mousavi, Seied Aasadollah, et al.
Publicado: (2018)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation
por: Jung, Hye Ryun, et al.
Publicado: (2011)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Eligibility for subcutaneous implantable cardioverter‐defibrillator in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.
por: Fazio, F, et al.
Publicado: (2022)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

1215. Evaluation of the Carba-R NxG Assay in a Global Challenge Set of Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2020)

Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases
por: Li, Jianglei, et al.
Publicado: (2022)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

1215. Variation in Hand Hygiene Improvement After Implementation of an Electronic Hand Hygiene System During the COVID-19 Pandemic
por: Steinberg, James P, et al.
Publicado: (2022)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
por: Rosenthal, Allison, et al.
Publicado: (2023)

Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Hwang, William Y. K., et al.
Publicado: (2009)

Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma
por: Terziev, Denis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qssj2nmlcl5c0kl07cgrpa7c7n